載入...
IMMU-02. TARGETING CD200 ACTIVATION RECEPTORS TO OVERCOME THE IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT: A NEW DIRECTION FOR CHECKPOINT IMMUNOTHERAPY
Glioblastoma multiforme is an incurable primary brain tumor. The standard of care consists of resection followed by radiation and chemotherapy is associated with a median overall survival of 14.6 months. To address this dismal outcome, aggressive interventions need to be pursued. Recently, the FDA a...
Na minha lista:
| 發表在: | Neuro Oncol |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5475077/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.113 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|